Lastly, the lack of data on lifestyle and socioeconomic variables, including diet, exercise, and financial constraints, may confound outcome interpretation.In mild obesity post-MS, liraglutide 3.0 mg/day or GLP-1/GIP dual agonists may be required for optimal results. Here, GIP is linked to obesity disorder.